The research areas Community-Acquired Infections at Mucosal Interfaces, Hepatitis and Tuberculosis are coordinated from München, as is the field of Infections of the Immunocompromised Host in co-coordination. Scientists at the DZIF site in München are also working on immune control of infections, defence against emerging infectious dieseases and the development of new therepeutic methods. Pathogen-specific immunotherapies (e.g. vaccinations or (adoptive) T-cell transfer) are aimed at strengthening the body’s own immune defence system in order to better control or completely prevent infectious diseases. Further focal points an the München site are HIV and the infrastructure Biobanking (since 1/2021 part of the TI Bioresources, Biodata and Digital Health), as well as the International Clinical Trials Unit—a central service facility of the DZIF for the coordination of global studies on various research topics (e.g. tuberculosis, HIV, hepatitis B and SARS-CoV-2).